Results 51 to 60 of about 6,511 (194)

Protective Role of Sarpogrelate in Combination with Bromocriptine and Cabergoline for Treatment of Diabetes in Alloxan-induced Diabetic Rats

Current Therapeutic Research, 2021
: Background: Although dopamine D2 receptor agonists, bromocriptine and cabergoline, are notable medications in the treatment of Parkinsonism, hyperprolactinemia, and hyperglycemia, there is an identified relationship between the utilization of D2-like ...
Mohammed Fouad Shalaby, MD, Hekma A. Abd El Latif, PhD, Mohamed El Yamani, PhD, May Ahmed Galal, PhD, Sherifa Kamal, PhD, Ikhlas Sindi, PhD   +5 more
doaj   +1 more source

Cabergoline for Cushing's disease: a large retrospective multicenter study.

, 2017
peer reviewedOBJECTIVE: The efficacy of cabergoline in Cushing's disease (CD) is controversial. The aim of this study was to assess the efficacy and tolerability of cabergoline in a large contemporary cohort of patients with CD.
Chabre, Olivier, Cortet, Chrisitine, Delemer, B., Maiter, D., Briet, C., Beckers, Albert, Cephise-Velayoudom, F. L., Tabarin, Antoine, Maiter, Dominique, Castinetti, Frédéric, Chanson, Philippe, Castinetti, F., Haissaguerre, M., Briet, Claire, Caron, Philippe, Ferriere, Amandine, Delemer, Brigitte, Nunes, M. L., Raingeard, I., Bertherat, Jérôme, Cephise-Velayoudom, Fritz Line, Haissaguerre, Magalie, Caron, P., Reznik, Yves, Rohmer, Vincent, Chabre, O., Nunes, Marie Laure, Chanson, P., Cortet, C., Rohmer, V., Tabarin, A., VROONEN, Laurent, Ferriere, A., Reznik, Y., Raingeard, Isabelle, Bertherat, J.   +35 more
core   +1 more source

ACTH silent adenoma shrinking under cabergoline. [PDF]

, 2001
peer reviewedOBJECTIVES: The authors present a case report that proposes the use of cabergoline treatment in silent ACTH adenoma, an unusual member of the heterogeneous group of the so-called clinically non-functioning pituitary adenomas.
Petrossians, Patrick, Kalife, A., Stevenaert, Achille, Tabarin, A., Valdes Socin, Hernan Gonzalo, Ronci, N., Bloch, B., Beckers, Albert   +7 more
core   +1 more source

The Effect of Dopaminergic Medication on Impulse Control and Compulsive Behaviour: A Translational Perspective

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 1, July 2026.
ABSTRACT Dopaminergic medication used in disorders like Parkinson's disease (PD) and restless legs syndrome can cause impulsive‐compulsive behaviour (ICB), often with strong negative effects on patients' quality of life. This narrative review presents translational evidence on iatrogenic ICB, taking findings from epidemiological, clinical, neuroimaging
Mirjam Wolfschlag, Elena Espa, Kevin Oliveira Hauer, Jonathan Timpka, Ruben Smith, Per Odin, Maria Angela Cenci, Anders Håkansson   +7 more
wiley   +1 more source

Cabergoline induced upregulation of glutamate transporters.

, 2014
(A) Pretreatment with cabergoline reduced H2O2-induced extracellular glutamate accumulation. Pretreatment with cabergoline was performed 24 hours before H2O2 application.
Naoki Adachi (575911), Takafumi Inoue (575915), Yoshiko Ooshima (575912), Haruki Odaka (575909), Yusuke Katanuma (575914), Hiroshi Kunugi (276981), Tadahiro Numakawa (575910), Shingo Nakajima (575913)   +7 more
core   +1 more source

Oncogenic driver and therapeutic target: Prolactin signalling axis in retroperitoneal sarcoma

Clinical and Translational Medicine, Volume 16, Issue 5, May 2026.
Retroperitoneal sarcoma cells can secrete prolactin into the bloodstream, inducing hyperprolactinaemia, which subsequently triggers metabolic reprogramming, such as glucose metabolism. SOX4 can function as a transcription factor that facilitates PRL transcription.
Fu'an Xie, Lingwei Gu, Kunrong Yang, Shuai Wang, Mengmeng Xiao, Guangting Yan, Quan Zhang, Rubing Liang, Aobo Zhuang, Zhe Xi, Yujia Niu, Yanhua Chen, Xiaogang Xia, Linlin Qu, Bin Zhao, Weibing Li, Ting Wu, Chundong Yu, Chenghua Luo, Houzhao Wang, Lanlan Lian, Wengang Li   +21 more
wiley   +1 more source

Successful Management of a Giant Pituitary Lactosomatotroph Adenoma Only with Cabergoline

Case Reports in Endocrinology, 2013
Although advances in endocrinologic and neuroradiologic research allow easier recognition of pituitary adenomas, giant pituitary tumours are relatively rare.
Emre Bozkirli, Okan Bakiner, Emine Duygu Ersozlu Bozkirli, Eda Ertorer, Neslihan Bascil Tutuncu, Nilgun Guvener Demirag   +5 more
doaj   +1 more source

Effect of ondansetron for preventing of ovarian hyperstimulation syndrome: in an experimental rat model

Gynecological Endocrinology, 2022
Objective: Ovarian hyperstimulation syndrome is an iatrogenic condition that occurs in the treatment of infertility. There is no specific treatment available for OHSS.
Şükrü Bakırcı, Nevin Sağsöz, Tuba Devrim, Yaşar Şahin, Murat Bulanık, Hilal Gözüyukarı   +5 more
doaj   +1 more source

Matsupexole: A novel nonergot dopamine receptor agonist with sustained efficacy in a rat model of Parkinson's disease and limited off‐target activity

British Journal of Pharmacology, Volume 183, Issue 10, Page 2518-2532, May 2026.
Background and Purpose Dopamine receptor agonists, particularly targeting the dopamine D2L receptor (D2LR), have been used to treat Parkinson's disease (PD). However, valvular heart disease and somnolence, mainly caused by activating the serotonin 5‐HT2B receptor (5‐HT2BR) and dopamine D3 receptor (D3R), respectively, currently challenge their clinical
Takayuki Suzuki, Fumiki Oana, Masaki Oota, Yuma Handa, Osamu Kaminuma   +4 more
wiley   +1 more source

The Effectiveness of Cabergoline for the Prevention of Ovarian Hyperstimulation Syndrome [PDF]

Iranian Journal of Medical Sciences, 2011
Type 2 receptors for vascular endothelial growth factor are believed to be involved in the pathophysiology of ovarian hyperstimulation syndrome (OHSS).
Marzieh Agha Hosseini, Ashraf Aleyasin, Atossa Mahdavi, Romina Nezami, Leila Safdarian   +4 more
doaj